ACIU - ACイミュ―ン (AC Immune SA) ACイミュ―ン

 ACIUのチャート


 ACIUの企業情報

symbol ACIU
会社名 AC Immune SA (ACイミュ―ン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases such as Down syndrome glaucoma and Parkinson''s and focuses on producing therapeutic and diagnostic product candidates using SupraAntigen and Morphomer technology platforms. The Company''s pipeline includes Crenezumab ACI-24 Anti-Tau antibody Morphomer Tau Tau-PET imaging agent Morphomer Abeta and Morphomer alpha-syn among others.   ACイミュ―ンはスイスのバイオ医薬品企業。臨床段階で、細胞内のタンパク質の折りたたみ異常に起因する神経変性疾患の特定や治療薬の開発に従事する。広範囲の神経変性疾患を対象にパ―キンソン病、ダウン症、緑内障の予防や診断、治療に対応するために抗体や小分子、ワクチンを作成する。本社はラウサネ。   AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
本社所在地 EPFL Innovation Park Building B Lausanne 1015 CHE
代表者氏名 Martin Velasco マーティンベラスコ
代表者役職名 Chairman of the Board of Directors
電話番号 +41 21-345-9121
設立年月日 37653
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数
url www.acimmune.com
nasdaq_url https://www.nasdaq.com/symbol/aciu
adr_tso
EBITDA EBITDA(百万ドル) -28.79702
終値(lastsale) 7.35
時価総額(marketcap) 495115771.5
時価総額 時価総額(百万ドル) 527.14420
売上高 売上高(百万ドル) 21.15660
企業価値(EV) 企業価値(EV)(百万ドル) 424.17964
当期純利益 当期純利益(百万ドル) -27.61319
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 AC Immune SA revenues increased 26% to SF3.5M. Net loss increased 4% to SF22.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Operating Expense - R&D increase of 57% to SF15.2M (expense) Labor_Related Expenses in R&D increase from SF2.2M to SF5.4M (expense).

 ACIUのテクニカル分析


 ACIUのニュース

   AC Immune (ACIU) Expected to Beat Earnings Estimates: Should You Buy?  2019/11/05 15:33:45 Zacks Investment Research
AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   AC Immune to Earn Milestone From Lilly for Alzheimer's Drug  2019/09/23 17:22:00 Zacks Investment Research
AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.
   Analysts Estimate AC Immune (ACIU) to Report a Decline in Earnings: What to Look Out for  2019/08/07 14:30:34 Zacks Investment Research
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   AC Immune Initiates Phase I Study for Alzheimer's Disease  2019/07/18 14:26:00 Zacks Investment Research
AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.
   AC Immune (ACIU) Lags Q1 Earnings and Revenue Estimates  2019/05/15 12:35:02 Zacks Investment Research
AC Immune (ACIU) delivered earnings and revenue surprises of -36.09% and -29.52%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
   AC Immune +3% on new data on alpha-synuclein PET tracer  2019-03-29
AC Immune SA (NASDAQ: ACIU ) presents new data on its positron-emission tomography (PET) tracer, which demonstrated a high-affinity binding to human Parkinsons disease-brain derived alpha-synuclein (a-syn),potentially capable of accurately detecting and monitoring progression…
   AC Immune +3% on new data on alpha-synuclein PET tracer  2019-03-29
AC Immune SA (NASDAQ: ACIU ) presents new data on its positron-emission tomography (PET) tracer, which demonstrated a high-affinity binding to human Parkinsons disease-brain derived alpha-synuclein (a-syn),potentially capable of accurately detecting and monitoring progression…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ACイミュ―ン ACIU AC Immune SA)

 twitter  (公式ツイッターやCEOツイッターなど)